moxifloxacin has been researched along with lomefloxacin in 25 studies
| Studies (moxifloxacin) | Trials (moxifloxacin) | Recent Studies (post-2010) (moxifloxacin) | Studies (lomefloxacin) | Trials (lomefloxacin) | Recent Studies (post-2010) (lomefloxacin) |
|---|---|---|---|---|---|
| 3,157 | 552 | 1,690 | 620 | 83 | 134 |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 1 (4.00) | 18.2507 |
| 2000's | 13 (52.00) | 29.6817 |
| 2010's | 9 (36.00) | 24.3611 |
| 2020's | 2 (8.00) | 2.80 |
| Authors | Studies |
|---|---|
| Baroni, M; Cecchetti, V; Cianchetta, G; Cruciani, G; Mannhold, R | 1 |
| Arakawa, Y; Kato, H; Kimura, K; Konda, T; Shibata, N; Shibayama, K; Suzuki, S; Wachino, J; Yamane, K | 1 |
| Azéma, J; Dewelle, J; Guidetti, B; Kiss, R; Korolyov, A; Le Calve, B; Malet-Martino, M; Martino, R; Mijatovic, T; Vaysse, J | 1 |
| Sen, S; Sinha, N | 1 |
| Bellman, K; Knegtel, RM; Settimo, L | 1 |
| Chen, M; Hu, C; Suzuki, A; Thakkar, S; Tong, W; Yu, K | 1 |
| Bai, L; Deng, JL; Gao, F; Lv, ZS; Wang, Y; Xu, Z; Zhang, F; Zhao, SJ | 1 |
| Ciura, K; Fallarero, A; Fedorowicz, J; Gilbert-Girard, S; Konopacka, A; Lejnowski, D; Morawska, M; Sączewski, J; Savijoki, K; Skok, Ž; Tomašič, T; Waleron, K | 1 |
| Blaskovich, MAT; Pham, TDM; Ziora, ZM | 1 |
| Ferguson, J; Man, I; Murphy, J | 1 |
| Chiang, SR; Chuang, YC; Ko, WC; Lee, HC; Tang, HJ; Wang, YY | 1 |
| Holzgrabe, U; Kiefer, W; Neugebauer, U; Popp, J; Schmitt, M; Szeghalmi, A | 1 |
| Dashieva, DG; Elistratova, NA; Mikhaĭlova, LP; Mozhokina, GN; Sokolova, GB | 1 |
| Paramasivan, CN; Rahman, F; Sulochana, S | 1 |
| Depta, JP; Pichler, WJ; Schmid, DA | 1 |
| Bayar, B; Bozkurt, A; Dinçel, A; Duman, S; Kaya, E; Oflu, Y; Yağci, R; Yağci, S | 1 |
| Abd-El-Fattah, Lel-S; El-Guindi, NM; Mikael, HK; Salem, MY | 1 |
| Berkner, L; Hazarbassanov, R; Michaeli, A; Regenbogen, M; Varssano, D; Waisbourd, M | 1 |
| Carda-Broch, S; Esteve-Romero, J; Rambla-Alegre, M | 1 |
| Anisimov, BI; Ryzhko, IV; Trishina, AV; Tsuraeva, RI | 1 |
| Bharathi, N; Muruganathan, G; Nair, DK; Ravi, TK | 1 |
| Betlejewska-Kielak, K; Biernacka, J; Grudzień, M; Kłosińska-Szmurło, E; Mazurek, AP; Pluciński, F | 1 |
| Beberok, A; Buszman, E; Delijewski, M; Otręba, M; Respondek, M; Rok, J; Rzepka, Z; Wrześniok, D | 1 |
| Banach, K; Beberok, A; Kowalska, J; Rok, J; Rzepka, Z; Wrześniok, D | 2 |
3 review(s) available for moxifloxacin and lomefloxacin
| Article | Year |
|---|---|
DILIrank: the largest reference drug list ranked by the risk for developing drug-induced liver injury in humans.
Topics: Chemical and Drug Induced Liver Injury; Databases, Factual; Drug Labeling; Humans; Pharmaceutical Preparations; Risk | 2016 |
Fluoroquinolone-isatin hybrids and their biological activities.
Topics: Anti-Bacterial Agents; Anti-Infective Agents; Antineoplastic Agents; Antitubercular Agents; Antiviral Agents; Fluoroquinolones; Humans; Isatin; Structure-Activity Relationship | 2019 |
Quinolone antibiotics.
Topics: | 2019 |
1 trial(s) available for moxifloxacin and lomefloxacin
| Article | Year |
|---|---|
Fluoroquinolone phototoxicity: a comparison of moxifloxacin and lomefloxacin in normal volunteers.
Topics: Adult; Anti-Infective Agents; Aza Compounds; Dermatitis, Phototoxic; Double-Blind Method; Fluoroquinolones; Humans; Male; Moxifloxacin; Photosensitizing Agents; Quinolines; Quinolones | 1999 |
21 other study(ies) available for moxifloxacin and lomefloxacin
| Article | Year |
|---|---|
Chemometric studies on the bactericidal activity of quinolones via an extended VolSurf approach.
Topics: Anti-Bacterial Agents; Enterococcus faecalis; Escherichia coli; Models, Molecular; Pseudomonas aeruginosa; Quantitative Structure-Activity Relationship; Quinolones; Staphylococcus aureus; Thermodynamics | 2004 |
New plasmid-mediated fluoroquinolone efflux pump, QepA, found in an Escherichia coli clinical isolate.
Topics: Amino Acid Sequence; Anti-Bacterial Agents; Carbonyl Cyanide m-Chlorophenyl Hydrazone; Chitosan; Conjugation, Genetic; DNA, Bacterial; Drug Resistance, Bacterial; Escherichia coli; Escherichia coli Infections; Fluoroquinolones; Humans; Malates; Microbial Sensitivity Tests; Molecular Sequence Data; Plasmids; Reverse Transcriptase Polymerase Chain Reaction; Transformation, Bacterial; Uncoupling Agents | 2007 |
7-((4-Substituted)piperazin-1-yl) derivatives of ciprofloxacin: synthesis and in vitro biological evaluation as potential antitumor agents.
Topics: Animals; Antineoplastic Agents; Cell Line, Tumor; Cell Proliferation; Ciprofloxacin; Humans; Maximum Tolerated Dose; Mice; Neoplasms; Piperazine; Piperazines | 2009 |
Predicting hERG activities of compounds from their 3D structures: development and evaluation of a global descriptors based QSAR model.
Topics: Computer Simulation; Ether-A-Go-Go Potassium Channels; Humans; Molecular Structure; Organic Chemicals; Quantitative Structure-Activity Relationship | 2011 |
Comparison of the accuracy of experimental and predicted pKa values of basic and acidic compounds.
Topics: Chemistry, Pharmaceutical; Forecasting; Hydrogen-Ion Concentration; Pharmaceutical Preparations; Random Allocation | 2014 |
Synthesis and biological evaluation of hybrid quinolone-based quaternary ammonium antibacterial agents.
Topics: Anti-Bacterial Agents; DNA Gyrase; DNA Topoisomerase IV; Dose-Response Relationship, Drug; Enzyme Inhibitors; Gram-Negative Bacteria; Gram-Positive Bacteria; HEK293 Cells; Humans; Microbial Sensitivity Tests; Molecular Structure; Quaternary Ammonium Compounds; Quinolones; Structure-Activity Relationship | 2019 |
In vitro and in vivo activities of fluoroquinolones against Aeromonas hydrophila.
Topics: Aeromonas hydrophila; Animals; Anti-Bacterial Agents; Anti-Infective Agents; Aza Compounds; Cefotaxime; Ciprofloxacin; Fluoroquinolones; Gatifloxacin; Gram-Negative Bacterial Infections; Humans; In Vitro Techniques; Levofloxacin; Mice; Mice, Inbred BALB C; Microbial Sensitivity Tests; Minocycline; Moxifloxacin; Ofloxacin; Quinolines; Quinolones | 2003 |
Vibrational spectroscopic characterization of fluoroquinolones.
Topics: Aza Compounds; Cinoxacin; Ciprofloxacin; DNA Gyrase; DNA, Bacterial; Enoxacin; Enzyme Inhibitors; Fluoroquinolones; Hydrogen Bonding; Hydrogen-Ion Concentration; Models, Chemical; Models, Molecular; Models, Theoretical; Moxifloxacin; Nalidixic Acid; Norfloxacin; Ofloxacin; Oxolinic Acid; Quinolines; Quinolones; Spectrophotometry, Infrared; Spectrum Analysis, Raman; Temperature; Ultraviolet Rays; Vibration; Water | 2005 |
[Comparative efficiency of treatment with moxyfloxacin and lomefloxacin for generalized murine tuberculosis caused by drug-resistant Mycobacterium strains].
Topics: Animals; Antitubercular Agents; Aza Compounds; Disease Models, Animal; Drug Therapy, Combination; Fluoroquinolones; Liver; Lung; Mice; Moxifloxacin; Mycobacterium tuberculosis; Quinolines; Quinolones; Treatment Outcome; Tuberculosis, Multidrug-Resistant | 2005 |
In vitro activity of fluoroquinolones against Mycobacterium tuberculosis.
Topics: Aza Compounds; Ciprofloxacin; Drug Resistance, Bacterial; Fluoroquinolones; Gatifloxacin; Humans; Microbial Sensitivity Tests; Moxifloxacin; Mycobacterium tuberculosis; Ofloxacin; Quinolines; Quinolones; Sampling Studies; Sensitivity and Specificity | 2005 |
T cell-mediated hypersensitivity to quinolones: mechanisms and cross-reactivity.
Topics: Adult; Aged; Aged, 80 and over; Anti-Bacterial Agents; Antigen-Presenting Cells; Aza Compounds; Cell Proliferation; Cells, Cultured; Ciprofloxacin; Clone Cells; Cross Reactions; Drug Hypersensitivity; Enoxacin; Female; Fluoroquinolones; Humans; Hypersensitivity, Delayed; Middle Aged; Moxifloxacin; Nalidixic Acid; Norfloxacin; Ofloxacin; Patch Tests; Pipemidic Acid; Quinolines; Quinolones; T-Lymphocytes | 2006 |
Penetration of second-, third-, and fourth-generation topical fluoroquinolone into aqueous and vitreous humour in a rabbit endophthalmitis model.
Topics: Animals; Anti-Bacterial Agents; Aqueous Humor; Aza Compounds; Ciprofloxacin; Disease Models, Animal; Endophthalmitis; Eye Infections, Bacterial; Fluoroquinolones; Levofloxacin; Moxifloxacin; Ofloxacin; Ophthalmic Solutions; Quinolines; Rabbits; Staphylococcal Infections; Vitreous Body | 2007 |
Stability indicating methods for the determination of some fluoroquinolones in the presence of their decarboxylated degrades.
Topics: Aza Compounds; Chromatography, Thin Layer; Densitometry; Drug Stability; Fluoroquinolones; Molecular Structure; Moxifloxacin; Quinolines; Spectrophotometry | 2006 |
Late-onset laser in situ keratomileusis-related corneal ulcer--a case series.
Topics: Administration, Topical; Adult; Anti-Bacterial Agents; Anti-Infective Agents; Aza Compounds; Corneal Ulcer; Eye Infections, Bacterial; Fluoroquinolones; Humans; Keratomileusis, Laser In Situ; Male; Middle Aged; Moxifloxacin; Quinolines; Retrospective Studies; Staphylococcal Infections; Streptococcal Infections; Surgical Flaps; Time Factors | 2009 |
Validation of a MLC method with fluorescence detection for the determination of quinolones in urine samples by direct injection.
Topics: Anti-Bacterial Agents; Aza Compounds; Calibration; Chromatography, High Pressure Liquid; Ciprofloxacin; Fluorescence; Fluoroquinolones; Humans; Levofloxacin; Moxifloxacin; Ofloxacin; Quinolines; Quinolones; Reproducibility of Results | 2009 |
[Efficacy of levofloxacin, lomefloxacin and moxifloxacin vs. other fluoroquinolones in experimental plague due to FI+ and FI- strains of Yersinia pestis in Albino mice].
Topics: Animals; Anti-Bacterial Agents; Aza Compounds; Disease Models, Animal; Dose-Response Relationship, Drug; Fluoroquinolones; Humans; Levofloxacin; Mice; Moxifloxacin; Ofloxacin; Plague; Quinolines; Species Specificity; Time Factors; Yersinia pestis | 2009 |
Interaction study of moxifloxacin and lomefloxacin with co-administered drugs.
Topics: Aluminum Hydroxide; Anti-Infective Agents; Aza Compounds; Chromatography, High Pressure Liquid; Drug Combinations; Drug Interactions; Erythromycin; Fluoroquinolones; Hydrogen-Ion Concentration; In Vitro Techniques; Magnesium Hydroxide; Minerals; Moxifloxacin; Quinolines; Silicic Acid; Solubility; Sucralfate; Tablets; Temperature | 2011 |
Physicochemical properties of lomefloxacin, levofloxacin, and moxifloxacin relevant to the biopharmaceutics classification system.
Topics: Anti-Bacterial Agents; Biopharmaceutics; Chemistry, Pharmaceutical; Electrochemistry; Fluoroquinolones; Gastrointestinal Tract; Humans; Hydrogen-Ion Concentration; Levofloxacin; Models, Molecular; Molecular Conformation; Moxifloxacin; Permeability; Phosphates; Potentiometry; Protons; Quantum Theory; Solubility; Solvents; Static Electricity; Temperature | 2014 |
Effect of fluoroquinolones on melanogenesis in normal human melanocytes HEMn-DP: a comparative in vitro study.
Topics: Anti-Bacterial Agents; Cell Line; Cell Survival; Ciprofloxacin; Dermatitis, Phototoxic; Epidermal Cells; Epidermis; Fluoroquinolones; Humans; Melanins; Melanocytes; Monophenol Monooxygenase; Moxifloxacin; Spectrophotometry | 2017 |
Molecular and Biochemical Basis of Fluoroquinolones-Induced Phototoxicity-The Study of Antioxidant System in Human Melanocytes Exposed to UV-A Radiation.
Topics: Anti-Bacterial Agents; Antioxidants; Catalase; Fluoroquinolones; Gene Expression Regulation, Enzymologic; Glutathione Peroxidase; Humans; Melanins; Melanocytes; Moxifloxacin; Oxidative Stress; Skin; Superoxide Dismutase; Ultraviolet Rays | 2020 |
The Biochemical and Molecular Analysis of Changes in Melanogenesis Induced by UVA-Activated Fluoroquinolones-In Vitro Study on Human Normal Melanocytes.
Topics: Cell Death; Cell Survival; Fluoroquinolones; Gene Expression Regulation; Humans; Melanins; Melanocytes; Microphthalmia-Associated Transcription Factor; Monophenol Monooxygenase; Moxifloxacin; RNA, Messenger; Ultraviolet Rays | 2021 |